妊娠期糖尿病妇女孕晚期每日早餐前补充乳清蛋白降低餐后血糖:一项随机对照临床试验
该双盲随机对照试验纳入62例妊娠期糖尿病(GDM)妇女,比较每日早餐前30分钟补充20克乳清蛋白分离物与安慰剂对血糖的影响。主要结局为血糖变异系数(CV%)。结果显示乳清蛋白组在控食条件下早餐后1小时血糖在孕早期和孕晚期分别降低20%和15%,血糖变异指标亦改善。结论认为餐前乳清蛋白可改善GDM妇女的血糖管理。
要点
- 每日早餐前30分钟补充20克乳清蛋白可降低GDM妇女早餐后1小时血糖。
- 乳清蛋白补充可改善控食条件下的血糖变异指标(MAGE、SD、CV%)。
- 自由生活条件下孕晚期血糖在目标范围时间(3.5-7.8 mmol/l)有降低趋势(p=0.05)。
核心结论
- 餐前补充乳清蛋白可改善GDM妇女在控食和自由生活条件下的血糖管理并降低血糖变异。
- 未来研究应评估乳清蛋白能否延迟或预防胰岛素等药物治疗的启动。
研究设计与样本
- 双盲、随机、安慰剂对照、平行组临床试验,纳入62例GDM妇女,随机分为乳清蛋白组(33例)和安慰剂组(29例)。
- 干预为每日早餐前30分钟补充20克乳清蛋白分离物或安慰剂,贯穿整个孕晚期。
- 采用连续血糖监测评估血糖,包括实验室访视和家庭测量(控食和自由生活条件),随访至分娩。
主要发现
- 控食条件下,乳清蛋白组早餐后1小时血糖在孕早期降低20%(95%CI -28%, -11%),孕晚期降低15%(95%CI -24%, -5%),均优于安慰剂组。
- 自由生活条件下,乳清蛋白组早餐后1小时血糖在孕早期降低14%(95%CI -23%, -4%),孕晚期降低8%(95%CI -18%, 3%)。
- 控食条件下乳清蛋白组血糖变异更低:MAGE在孕早期和孕晚期均降低,SD和CV%在孕早期降低(均p<0.05)。
- 自由生活条件下孕晚期血糖在目标范围时间(3.5-7.8 mmol/l)降低(p=0.05)。
临床怎么用
- 对于GDM妇女,可考虑在早餐前30分钟补充20克乳清蛋白分离物以改善餐后血糖和血糖变异。
- 需注意自由生活条件下孕晚期血糖在目标范围时间有降低趋势,应个体化评估获益与风险。
局限性
- 研究未报告样本量计算依据及主要结局CV%的具体数值。
- 自由生活条件下孕晚期早餐后1小时血糖的95%CI包含0(-18%, 3%),差异无统计学显著性。
- 研究排除了多囊卵巢综合征、双胎妊娠等合并症,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: This study aimed to investigate how pre-meal whey protein (WP) supplementation throughout the third trimester of pregnancy affects glycaemic and metabolic outcomes in women with gestational diabetes mellitus (GDM). The hypothesis was that WP, when administered as a pre-meal 30 min before breakfast daily, lowers glycaemic variability (primary outcome: CV%). METHODS: In a double-blinded, randomised, placebo-controlled, parallel trial, 62 women with GDM were randomised to receive 20 g WP isolate/day or placebo 30 min before breakfast throughout the third trimester. Participants were randomly assigned ( www.randomiser.org ) to WP or placebo using a computer-generated list. Allocation was concealed with sealed strips. Participants, caregivers, investigators and outcome assessors were masked, except the dietitian providing dietary guidance. Eligibility criteria included GDM, normotension and age ≥18 years. Exclusion criteria included special dietary regimens ≥1 month, daily protein supplements, food allergies, glucose-metabolism-affecting drugs, twin pregnancies, polycystic ovary syndrome, severe comorbidity, hyperemesis or non-breakfast eaters. The study included laboratory visits, home-based measurements under controlled-living and free-living conditions during the early and late third trimester, and follow-up at delivery. Glucose levels were assessed using continuous glucose monitoring. RESULTS: A total of 29 women were randomised to placebo and 33 were randomised to WP, with 25 in the placebo group and 30 women in the WP group completing the study. In the WP group, the 1 h postprandial glucose following breakfast was -20% (95% CI -28%, -11%) lower in the early and -15% (95% CI -24%, -5%) lower in the late third trimester compared with the placebo group under controlled conditions. Similarly, the 1 h postprandial glucose was -14% (95% CI -23%, -4%) lower in the early and -8% (95% CI -18%, 3%) lower in the late third trimester under free-living conditions. Glycaemic variability was lower in the WP group under controlled-living conditions. The mean amplitude of glycaemic excursions (MAGE) was lower during both the early and late third trimester, and the SD and CV% were lower during the early third trimester (all p<0.05). Time in range (proportion of time spent with glucose levels 3.5-7.8 mmol/l) was lower during free-living in the late third trimester (p=0.05). CONCLUSIONS/INTERPRETATION: Pre-meal WP improves glycaemic management and reduces glucose variability in women with GDM under controlled-living and free-living conditions. Future research should evaluate whether WP can delay or prevent pharmacological treatments such as insulin initiation. TRIAL REGISTRATION: ClinicalTrials.gov NCT04767880 FUNDING: Department of Clinical Medicine, Aarhus University and Arla Foods Ingredients Group P/S (Agr-2020-731-12107).
引用
- Smedegaard S, Rittig N, Ovesen PG, et al. Once-daily supplementation with pre-meal whey protein lowers breakfast postprandial glucose levels in women with GDM throughout the third trimester: a randomised, controlled, clinical trial. Diabetologia. 2025. PMID: 41203981. doi:10.1007/s00125-025-06587-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。